Sandu Pharmaceuticals
40.30
+2.46(+6.50%)
Market Cap₹38.98 Cr
PE Ratio23.50
IndustryHealthcare
Company Performance:
1D+6.50%
1M+2.03%
6M-20.23%
1Y-26.79%
5Y+6.19%
View Company Insightsright
More news about Sandu Pharmaceuticals
13Aug 25
Sandu Pharmaceuticals Reports Q1 Profit, Declares Dividend, and Schedules 40th AGM
Sandu Pharmaceuticals reported Q1 revenue of Rs 1665.90 lakhs and profit after tax of Rs 22.33 lakhs. The Board declared a dividend of Rs 0.80 per share (8% of paid-up capital). The 40th AGM is scheduled for September 30 via video conferencing, with a book closure period from September 23-30. The company approved continuation of material related party transactions with Sandu Brothers Private Limited and the extension of CFO Shri Vijay Kajarekar's tenure beyond 70 years, both subject to shareholder approval.
16Jun 25
Sun Pharma's Halol Facility Faces FDA Scrutiny; Leadership Transition Announced
Sun Pharmaceuticals received eight FDA observations for its Halol facility, which is already under import alert. The company also announced a leadership transition, with Kirti Ganorkar set to become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi.
Sandu Pharmaceuticals
40.30
+2.46
(+6.50%)
1 Year Returns:-26.79%
Industry Peers
Sun Pharmaceutical
1,782.60
(+1.27%)
Divis Laboratories
6,642.50
(0.0%)
Torrent Pharmaceuticals
4,092.20
(+3.95%)
Cipla
1,467.90
(-4.11%)
Dr Reddys Laboratories
1,242.80
(-1.07%)
Lupin
2,214.30
(+3.01%)
Mankind Pharma
2,311.80
(+3.17%)
Zydus Life Science
927.55
(-0.38%)
Aurobindo Pharma
1,235.40
(+0.33%)
Alkem Laboratories
5,806.50
(+2.67%)